Euroasian journal of hepato-gastroenterology

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  14 (2024)
Volume  13 (2023)
Volume  12 (2022)
Volume  11 (2021)
Volume  10 (2020)
Volume  9 (2019)
Volume  8 (2018)
Volume  7 (2017)
Volume  6 (2016)
Volume  5 (2015)
Volume  4 (2014)
Volume  3 (2013)
Volume  2 (2012)
Volume  1 (2011)
Related articles

VOLUME 14 , ISSUE 1 ( January-June, 2024 ) > List of Articles

REVIEW ARTICLE

High Dose Pantoprazole for Gastroesophageal Reflux Disease: Need, Evidence, Guidelines and Our Experience

Rajesh Upadhyay, Navin K Soni, Ashwin A Kotamkar, Azra Naseem, Aaditi Phadke, Shreshth Nayar, Shailesh Pallewar, Parvan Shetty, Ashish Mungantiwar, Sunil Jaiswal, Amit Qamra

Keywords : Dual-drug release, Gastroesophageal reflux disease, High dose, Pantoprazole, Proton pump inhibitors

Citation Information : Upadhyay R, Soni NK, Kotamkar AA, Naseem A, Phadke A, Nayar S, Pallewar S, Shetty P, Mungantiwar A, Jaiswal S, Qamra A. High Dose Pantoprazole for Gastroesophageal Reflux Disease: Need, Evidence, Guidelines and Our Experience. Euroasian J Hepatogastroenterol 2024; 14 (1):86-91.

DOI: 10.5005/jp-journals-10018-1426

License: CC BY-NC 4.0

Published Online: 12-06-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Abstract

Gastroesophageal reflux disease (GERD) has a pooled prevalence of 15.2% in India with varying presentation in different subset of patients. The approach towards the management of GERD includes use of monotherapy or a combination of OTCs like antacids and/or prescription drugs like H2 receptor antagonists and proton pump inhibitors (PPI). Better efficacy and safety profile of PPIs have contributed to its wide spread use as compared with other drugs for the same indication. Among PPIs, most of the healthcare professionals prefer to prescribe pantoprazole in India. Standard dose of Pantoprazole (40 mg) is unable to meet the needs in case of extraesophageal symptoms, partial responders, patients with concomitant use of non-steroidal anti-inflammatory drugs (NSAIDs), or severe presentation in cases of overweight/obese patients. Multiple guidelines recommend doubling the dose of PPI in such cases. Twice daily dosing of PPI may reduce compliance. Thus, there is a need for a higher dose of Pantoprazole (80 mg) to be prescribed once daily in these cases so that improved compliance leads to better outcomes. The use of dual release Pantoprazole 80 mg may help to improve compliance and also enhance the time for which acid suppression takes place. In this review, we discuss the use of higher dose PPI based on scientific evidence and experience of clinicians for the same.

HTML PDF Share
  1. Dawoodi S, Dawoodi I, Dixit P. Gastrointestinal problem among Indian adults: Evidence from longitudinal aging study in India 2017–18. Front Public Health 2022;26(10):911354. DOI: 10.3389/fpubh.2022.911354.
  2. Ami D, Sperber AD, Shrikant I, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study. Gastroenterology 2021;160(1):99–114.e3. DOI: 10.1053/j.gastro.2020.04.014.
  3. Al Ghadeer HA, Alabbad ZE, AlShaikh SB, et al. Prevalence of gastroesophageal reflux disease and associated risk factors in the Eastern Region, Saudi Arabia. Cureus 2021;13(11):e19599. DOI: 10.7759/cureus.19599.
  4. Chowdhury SD, George G, Ramakrishna K, et al. Prevalence and factors associated with gastroesophageal reflux disease in southern India: A community-based study. Indian J Gastroenterol 2019;38(1):77–82. DOI: 10.1007/s12664-018-00931-6.
  5. Rai S, Kulkarni A, Ghoshal UC. Prevalence and risk factors for gastroesophageal reflux disease in the Indian population: A meta-analysis and meta-regression study. Indian J Gastroenterol 2021;40(2):209–219. DOI: 10.1007/s12664-020-01104-0.
  6. Rettura F, Bronzini F, Campigotto M, et al. Refractory gastroesophageal reflux disease: A management update. Front Med (Lausanne) 2021;8:765061. DOI: 10.3389/fmed.2021.765061.
  7. Yadlapati R, Gyawali CP, Pandolfino JE. AGA clinical practice update on the personalized approach to the evaluation and management of GERD. Clin Gastroenterol Hepatol 2022;20(5):984–994.e1. DOI: 10.1016/j.cgh.2022.01.025.
  8. Katz PO, Dunbar KB, Schnoll-Sussman FH, et al. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2022;117(1):27–56. DOI: 10.14309/ajg.0000000000001538.
  9. Antunes C, Aleem A, Curtis SA. Gastroesophageal reflux disease. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. PMID: 28722967.
  10. Sandhu DS, Fass R. Current trends in the management of gastroesophageal reflux disease. Gut Liver 2018;12(1):7–16. DOI: 10.5009/gnl16615.
  11. Clarrett DM, Hachem C. Gastroesophageal reflux disease (GERD). Mo Med 2018;115(3):214–218. PMID: 30228725.
  12. Ness-Jensen E, Hveem K, El-Serag H, et al. Lifestyle intervention in gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2016;14(2):175–82.e1–3. DOI: 10.1016/j.cgh.2015.04.176.
  13. Gu C, Olszewski T, King KL, et al. The effects of modifying amount and type of dietary carbohydrate on esophageal acid exposure time and esophageal reflux symptoms: A randomized controlled trial. Am J Gastroenterol 2022;117(10):1655–1667. DOI: 10.14309/ajg.0000000000001889.
  14. Bhatia S, Pareek KK, Kumar A, et al. API-ISG consensus guidelines for management of gastrooesophageal reflux disease. J Assoc Physicians India 2020;68(10):69–80. PMID: 32978931.
  15. Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis. Gastroenterology 1997;112(6):1798–1810. DOI: 10.1053/gast.1997.v112.pm9178669.
  16. Strand DS, Kim D, Peura DA. 25 years of proton pump inhibitors: A comprehensive review. Gut Liver 2017;11(1):27–37. DOI: 10.5009/gnl15502.
  17. M ZA, Lavu A, Ansari M, et al. A cross-sectional study on single-day use of proton pump inhibitors in tertiary care hospitals of South India. Hosp Pharm 2021;56(2):109–115. DOI: 10.1177/0018578719873876.
  18. FDA. Prescribing information. Accessible from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20987lbl.pdf.
  19. Jungnickel PW. Pantoprazole: A new proton pump inhibitor. Clin Ther 2000;22:1268–1293. DOI: 10.1016/s0149-2918(00)83025-8.
  20. Ang D, How CH, Ang TL. Persistent gastro-oesophageal reflux symptoms despite proton pump inhibitor therapy. Singapore Med J 2016;57(10):546–551. DOI: 10.11622/smedj.2016167.
  21. Cicala M, Emerenziani S, Guarino MP, et al. Proton pump inhibitor resistance, the real challenge in gastro-esophageal reflux disease. World J Gastroenterol 2013;19(39):6529–6535. DOI: 10.3748/wjg.v19.i39.6529.
  22. NICE [CG184]: Nov 2014. Gastro-oesophageal reflux disease and dyspepsia in adults: Investigation and management. Available from: https://www.nice.org.uk/guidance/cg184/evidence/full-guideline-pdf-193203757.
  23. Kunsch S, Neesse A, Linhart T, et al. Impact of pantoprazole on duodeno-gastro esophageal reflux (DGER). Gastroenterol 2009;47(3):277–282. DOI: 10.1055/s-2008-1027865.
  24. Chen W, Chang W, Tsai Y, et al. Double-dosed pantoprazole accelerates the sustained symptomatic response in overweight and obese patients with reflux esophagitis in Los Angeles Grades A and B. Am J Gastroenterol 2010;105(5):1046–1052. DOI: 10.1038/ajg.2009.632.
  25. Metz DC, Comer GM, Soffer E, et al. Three-year oral pantoprazole administration is effective for patients with Zollinger–Ellison syndrome and other hypersecretory conditions. Aliment Pharmacol Ther 2006;23(3):437–444. DOI: 10.1111/j.1365-2036.2006.02762.x.
  26. Matuz M, Benkő R, Engi Z et al. Use of proton pump inhibitors in Hungary: Mixed-method study to reveal scale and characteristics. Front Pharmacol 2020;8(11):552102. DOI: 10.3389/fphar.2020.552102.
  27. Kalaitzakis E, Björnsson E. A review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD). Ther Clin Risk Manag 2007;3(4):653–663. PMID: 18472988.
  28. Kardas P. Comparison of patient compliance with once-daily and twice-daily antibiotic regimens in respiratory tract infections: Results of a randomized trial. J Antimicrob Chemother 2007;59(3):531–536. DOI: 10.1093/jac/dkl528.
  29. Coleman CI, Limone B, Sobieraj DM, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm 2012;18(7):527–539. DOI: 10.18553/jmcp.2012.18.7.527.
  30. Laufs U, Rettig-Ewen V, Böhm M. Strategies to improve drug adherence. Eur Heart J 2011;32(3):264–268. DOI: 10.1093/eurheartj/ehq297.
  31. Srivastava K, Arora A, Kataria A, et al. Impact of reducing dosing frequency on adherence to oral therapies: A literature review and meta-analysis. Patient Prefer Adherence 2013;7:419–434. DOI: 10.2147/PPA.S44646.
  32. Metz DC, Vakily M, Dixit T, et al. Review article: Dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy. Aliment Pharmacol Ther 2009;29(9):928–937. DOI: 10.1111/j.1365-2036.2009.03984.x.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.